問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

1738Cases

2024-12-30 - 2031-06-30

Phase II

Active
THE RETIRE TRIAL: A RANDOMIZED PHASE 2 TRIAL OF ADOPTIVE THERAPY WITH TREG ADOPTIVE CELL TRANSFER (TRACT) TO PREVENT REJECTION IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS

  • Condition/Disease

    Kidney Transplantation

  • Test Drug

    TRK-001

Participate Sites
4Sites

Recruiting4Sites

2023-09-30 - 2026-06-30

Phase I

Active
A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TRX-920 Oral Gel (10 mg and 30 mg) in Patients With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumor

  • Test Drug

    TRX-920 Oral Gel 10 mg & 30 mg

Participate Sites
3Sites

Recruiting3Sites

2022-01-01 - 2026-03-31

Phase II

Active
A Phase 2, Open-Label Study of CVM-1118 in Combination With Nivolumab in Subjects With Unresectable Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    CVM-1118 膠囊 (又名 CVM-1118 速放膠囊 )

Participate Sites
6Sites

Recruiting6Sites

2025-06-01 - 2028-05-31

Phase III

Not yet recruiting
A Phase 3, Randomized, Multicenter, Parallel-arm, Double-blind Study to Compare Efficacy and Safety of EG1206A (EirGenix’ Pertuzumab) and Perjeta® (Pertuzumab) Sourced from EU as Neoadjuvant Treatment in Combination with Trastuzumab and Chemotherapy in Patients with HER2-positive Hormone Receptor-negative Early Breast Cancer

  • Condition/Disease

    HER2-positive Hormone Receptor-negative Early Breast Cancer

  • Test Drug

    injection

Participate Sites
11Sites

Recruiting11Sites

2023-02-01 - 2028-01-31

Phase II

Active
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of ADI-PEG 20 or Placebo in Subjects With Nonalcoholic Steatohepatitis (NASH)

  • Condition/Disease

    Nonalcoholic Steatohepatitis (NASH)

  • Test Drug

    ADI-PEG 20

Participate Sites
10Sites

Not yet recruiting6Sites

Recruiting4Sites

2017-06-08 - 2019-12-31

Phase I

Completed
Phase 1 Study of ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers.

  • Condition/Disease

    Advanced Solid Cancers

  • Test Drug

    ADI-PEG20

Participate Sites
1Sites

Terminated1Sites

2011-10-01 - 2013-09-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2017-05-16 - 2019-09-30

Phase I

Completed
Phase 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia

  • Condition/Disease

    Acute Myeloid Leukemia

  • Test Drug

    ADI-PEG 20

Participate Sites
3Sites

Terminated3Sites

陳彩雲
National Taiwan University Hospital

Division of General Internal Medicine

2012-10-01 - 2016-09-12

Phase II

Completed
Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia

  • Condition/Disease

    急性骨隨性白血病

  • Test Drug

    ADI-PEG 20

Participate Sites
5Sites

Terminated5Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2012-10-01 - 2014-09-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 91 92 93 94 95 174
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB